Crossmark

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis

Crossref DOI link: https://doi.org/10.1038/s41408-025-01376-9

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Finazzi, Maria Chiara https://orcid.org/0000-0002-1857-5836
Salmoiraghi, Silvia

Valsecchi, Francesca

Pavoni, Chiara

Belotti, Clara

Grassi, Anna

Algarotti, Alessandra

Lussana, Federico https://orcid.org/0000-0002-6510-8616
Rambaldi, Benedetta

Rizzuto, Giuliana

Cavallaro, Gianluca

Condorelli, Annalisa

Bellini, Marta

Spinelli, Orietta https://orcid.org/0000-0003-0374-1536
Rambaldi, Alessandro https://orcid.org/0000-0002-3739-7502
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 24 June 2025

Revised: 29 August 2025

Accepted: 17 September 2025

First Online: 21 October 2025

Competing interests

: The authors declare no competing interests.

: All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the Ethics Committee at the ASST Papa Giovanni XXIII, Bergamo, under reference number 1029.

: Informed consent was obtained from all participants before their inclusion in the study.

Document is current

Any future updates will be listed below